XML 104 R93.htm IDEA: XBRL DOCUMENT v3.25.3
Segment Reporting - Schedule of Reconciliation of Adjusted EBITDA (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Segment Reporting Information [Line Items]        
Revenue [1] $ 479,533 $ 621,401 $ 1,407,510 $ 1,908,199
Depreciation and amortization expenses 23,615 29,701 70,814 89,074
Interest income (964) (794) (3,322) (4,714)
Interest expense 16,475 6,010 38,461 18,002
Gain (loss) from equity method investees (156) 2,229 (334) 3,623
Provision from income taxes 906 (619) 1,551 (292)
Change in tax receivables agreement liability 0 0 0 (173)
Net loss attributable to common shareholders of Evolent Health, Inc. - basic (26,930) (31,231) (150,270) (62,839)
Net loss attributable to common shareholders of Evolent Health, Inc. - diluted (26,930) (31,231) (150,270) (62,839)
Total compensation expense by financial statement line item 14,682 14,416 37,343 45,861
Severance and termination benefits        
Segment Reporting Information [Line Items]        
Severance costs 1,540 1,680 3,345 2,860
Cost of revenue        
Segment Reporting Information [Line Items]        
Total compensation expense by financial statement line item 1,241 1,117 2,948 3,329
Selling, general and administrative expenses        
Segment Reporting Information [Line Items]        
Total compensation expense by financial statement line item 13,441 13,299 34,395 42,532
Transaction-related costs 551 2,072 1,254 2,235
Repositioning costs 0 0 0 10,599
Reportable segment        
Segment Reporting Information [Line Items]        
Revenue 479,533 621,401 1,407,510 1,908,199
Medical expense and device costs 274,628 448,596 816,466 1,333,657
Cost of revenue excluding medical expense and device costs and other segment items 103,890 90,995 285,466 279,571
Selling, general and administrative expenses excluding other segment items 62,060 50,009 192,216 157,123
Depreciation and amortization expenses 23,615 29,701 70,814 89,074
Interest income (964) (794) (3,322) (4,714)
Interest expense 16,475 6,010 38,461 18,002
Gain (loss) from equity method investees (156) 2,229 (334) 3,623
Provision from income taxes 906 (619) 1,551 (292)
Change in tax receivables agreement liability 0 0 0 173
Other segment items 26,009 26,505 156,462 94,821
Net loss attributable to common shareholders of Evolent Health, Inc. - basic (26,930) (31,231) (150,270) (62,839)
Net loss attributable to common shareholders of Evolent Health, Inc. - diluted $ (26,930) $ (31,231) $ (150,270) $ (62,839)
[1] See Note 18 for amounts attributable to unconsolidated related parties included in these line items.